The human 5-hydroxytryptamine-2C (5-HT 2C ) receptor has been the target of potential anxiolytics and antiobesity drugs, and its positive allosteric modulator was discovered to be L-threo-␣-D-galacto-octopyranoside, methyl-7-chloro-6,7,8-trideoxy-6-[[(4-undecyl-2-piperidinyl 69176E were observed with the human 5-HT 2C receptor expressed in several mammalian cell lines (human embryonic kidney 293, NIH3T3, and SH-EP) at variable receptor densities (6 to 45 pmol/mg of protein), but not with analogous 5-HT and dopamine receptors (human 5-HT 2A , 5-HT 2B , 5-HT 6 , 5-HT 7 , and dopamine D2-long and D3 receptors). Structurally, PNU-69176E consists of a long alkyl chain and a polar moiety, including the ␣-D-galactopyranoside. Its analogs with shorter alkyl chains (methyl to n-hexyl instead of n-undecyl group) failed to enhance [ 3 H]5-HT binding, and also long alkyl amides are without allosteric modulation. We propose that PNU-69176E may represent a new class of membrane receptor modulators, which probably need a long alkyl chain as a membrane anchor and target a selective polar head group to receptor modulatory sites near the membrane surface.
The 5-HT 2C receptor is a G protein-coupled receptor primarily distributed in the brain, and it mediates the release of intracellular inositol 1,4,5-triphosphate (IP 3 ) via activation of G q/11 and G i subtypes of G proteins (Conn et al., 1979; Julius et al., 1988; Salzman et al., 1991; Stam et al., 1994; Kaufman et al., 1995; Xie et al., 1996; Alberts et al., 1999) . Numerous studies implicated the receptor in a number of diseases such as anxiety, obesity, depression, schizophrenia, and affective disorders (Canton et al., 1990; Sanders-Bush and Breeding, 1991; Moreau et al., 1993; Dourish, 1995; Tecott et al., 1995; Cowen et al., 1996; Kennett et al., 1996; Epstein et al., 1997) . Recently, the receptor has become a therapeutic target for potential anxiolytics and antiobesity drugs (Dourish, 1995; Cowen et al., 1996; Kennett et al., 1996) . Much effort has been directed, so far, to the discovery of selective agonists for its serotonin binding site. Another potentially profitable approach could be a search of positive allosteric modulators, which could achieve greater receptor selectivity than the agents for 5-HT sites that are shared by many analogous 5-HT receptors and transporters. In this study, we searched for compounds that stimulate [ 3 H]5-HT binding, the seeming hallmark of positive allosteric modulators. We report the discovery and characterization of PNU-69176E as positive allosteric modulators that are highly selective for 5-HT 2C receptors.
Methods and Materials
Cloning of the cDNA for the human 5-HT 2C receptor into a mammalian expression vector, PCI-Neo (Promega, Madison, WI), has been described elsewhere (Alberts et al., 1999) and was cloned into the PCRscript vector via a blunt end ligation. The recombinant vector was used to transfect human embryonic kidney 293 cells (HEK293), NIH3T3, and a human epithelial cell line (SH-EP) using Ca 2ϩ phosphate precipitation techniques. Stably transfected cells were selected in the presence of G418 (400 g/ml). Cell membranes expressing the 5-HT 2C receptor were prepared with the use of procedures described elsewhere (Alberts et al., 1999) .
For [ 3 H]5-HT binding, scintillation proximity binding assays were initially carried out using wheat germ agglutinin-coated beads saturated with membranes from HEK293-A cell line expressing human 5-HT 2C receptors. Assay mixtures contained [
3 H]5-HT at 4 nM and test ligands from Pharmacia (Peapack, NJ) chemical library at 10 M in medium that contained 100 mM NaCl, 2 mM MgCl 2 , 1 mM EDTA, and 20 mM HEPES/Tris, pH 7.4. Nonspecific binding was measured in the presence of mianserin at 5 M. Hits from the high-throughput screening were further examined using regular filtration-binding techniques as described elsewhere (Alberts et al., 1999) . Briefly, binding of [ 3 H]5-HT or [ 3 H]mesulergine to 5-HT 2C membranes was measured in the above-described medium with use of the radioactive ligand at varying concentrations (0.1 to 20 nM for typical binding profiles) and 5 to 20 g membrane protein in a total volume of 500 l. Reaction mixtures were incubated at 23°C for 60 min and filtered over Whatman GF/B filters under vacuum (Whatman, Clifton, NJ), which were then washed three times with 4 ml of an ice-cold 50 mM Tris/HCl buffer, pH 7.4. Nonspecific binding was estimated in the presence of excess unlabeled clozapine (100 M). Ligand stock solutions were prepared in 0.1% ascorbic acid. Displacement of [ 3 H]mesulergine (2 nM) by test compounds at various concentrations (competition assay) was carried out in the same manner.
[ 35 S]GTP␥S binding was measured by following the procedure reported earlier (Chabert et al., 1994) in medium that contained 25 mM HEPES, pH 8.0, 100 mM NaCl, 1 mM EDTA, 3 mM MgCl 2 , 0.5 mM dithiothreitol, 0.003% mM digitonin, 2 nM [
35 S]GTP␥S (3 to 5 ϫ 10 5 cpm /assay), and approximately 10 g of membrane protein in a volume of 120 l. Membranes were preincubated with 100 M 5Ј-adenylylimidodiphosphate for 30 min at room temperature and subsequently with 10 M GDP for 10 min on ice. Test ligands were included at 10 M, unless indicated otherwise. Reaction mixtures were incubated for 45 min at 30°C and were filtered over a Whatman GF/B filter under vacuum. Filters were washed three times with 4 ml of an ice-cold buffer that contained 100 mM NaCl, 20 mM Tris/HCl, pH 8.0, and 25 mM MgCl 2 . Agonist-induced [
35 S]GTP␥S binding was obtained by subtracting that which was observed without agonists. Binding data were analyzed using a nonlinear regression method (Sigma plot).
The agonist-induced IP 3 release in intact cells was measured using the inositol-1,4,5-trisphophate 3 H radioreceptor assay kit from PerkinElmer Life Sciences (Boston, MA) . Briefly, cells were grown in a 24-well plate to approximately 80% confluence and were treated with 5-HT or test ligands at indicated concentrations for 45 s (initially a time course from 0 to 1200 s). Each reaction was stopped with trichloroacetic acid (20% final concentration), and each was then extracted with 1,1,2-trichloro-1,2,2-trifluoroethane and trioctyl amine. An aliquot (300 l) was analyzed for IP 3 3 H]inositol in 0.5 ml of Dulbecco's modified Eagle's medium without inositol for 24 h. After washing the cells, they were treated with 5-HT or PNU-69176E at 10 M in the presence of Li (10 mM) and pargyline (10 M) for 30 min. IPs were extracted from cells and isolated using an anion exchanger, AG1-X8 (formate form; Bio-Rad, Hercules, CA) column chromatography as described elsewhere (Berridge et al., 1982) .
Results
To search for positive allosteric modulators, the Pharmacia chemical library was screened with use of the assay of [ 3 H]5-HT binding to the human 5-HT 2C receptor. The receptor was heterologously expressed in HEK293 cells at a density of 45 Ϯ 3 pmol/mg of protein (HEK293-A). From the screening, we discovered PNU-69176E (Fig. 1 ), which at 10 M markedly stimulated [
3 H]5-HT (2 nM) binding (ϳ300%). The concentration-response profile for PNU-69176E was biphasic ( Fig. 2A) . At concentrations of less than 25 M, the drug (Fig. 1) . The biphasic profiles fitted to a two-site logistic equation. The stimulatory phase for PNU-69176E showed an EC 50 value of 6.3 Ϯ 1 M and a slope of 2.3 Ϯ 0.5, and the inhibitory phase showed an IC 50 value of 61 Ϯ 5 M and a slope of 3.6 Ϯ 0.6 (Table 1 ; Fig. 2A ). Also, saturation binding assays for [
3 H]5-HT at concentrations from 0.09 to 48 nM were carried out with or without PNU-69176E at 10 M (Fig. 2B) 3 H]mesulergine (2 Ϯ 0.2 nM) was largely unchanged, ranging from 95 to 115% of the control value. Its B max (43 pmol/mg of protein) also remained unchanged with PNU-69176E at concentrations up to 10 M, but at 25 M it decreased by approximately 45%, probably because of the sensitivity of the mesulergine binding site to the amphipathic property of PNU-69176E at high concentrations, as noted above (Fig. 3B) .
Typically, G protein-coupled receptors interact with agonists via high-and low-affinity sites, and their relative affinities can be examined with competition experiments using a radioactive antagonist. Displacement of [ (Fig. 2 ). This monophasic profile indicates more than 90% of receptors existing in low-affinity states for 5-HT, leaving only a negligible receptor population in high-affinity states, probably caused by high-receptor density of the cloned cells (Alberts et al., 1999) . PNU-69176E concentration-dependently shifted the displacement curve to the left (Fig. 3C) . The K i for 5-HT decreased from 159 Ϯ 12 to 86 Ϯ 10, 36 Ϯ 3, 10 Ϯ 1, and 6.4 Ϯ 0.9 nM in the presence of PNU-69176E at 2.5, 5, 10, and 20 M, respectively. Such parallel shifts of the displacement curve may indicate that the whole receptor population un- (Julius et al., 1988; Alberts et al., 1999) . Moreover, the ability of PNU-69176E to enhance 5-HT affinity was reversible. We treated 5-HT 2C membranes with PNU-69176E at 10 M for 30 min and then washed out upon dilution (4-fold) and ultracentrifugation. In such treated membranes, 5-HT replaced [ 3 H]mesulergine with a K i of 128 Ϯ 33 nM, which was not appreciably different from that of membranes which were not exposed to PNU-69176E at all.
Not only 5-HT but also other agonists improved their affinity to the 5-HT 2C receptor in the presence of PNU-69176E.
From competition experiments with [
3 H]mesulergine in the presence of PNU-69176E at 10 M, we found that the K i values of Org 37684, 1-(3-chlorophenyl)piperazine hydrochloride, 2,5-dimethoxy-4-iodoamphetamine, and 5-carboxamidotryptamine decreased by 12-, 8-, 7, and 3.4-fold, respectively: from 342 Ϯ 28 to 29 Ϯ 4 nM for Org 37684, from 228 Ϯ 12 to 32 Ϯ 2 nM for 2,5-dimethoxy-4-iodoamphetamine, from 523 Ϯ 81 to 64 Ϯ 12 nM for 1-(3-chlorophenyl)piperazine hydrochloride, and from 4081 Ϯ 612 to 1210 Ϯ 185 nM for 5-carboxamidotryptamine. In the same experiments, the K i for 5-HT decreased from 167 Ϯ 15 to 14 Ϯ 3 nM, approximately 12-fold. This indicates the universal action of PNU-69176E on 5-HT 2C agonists, albeit to somewhat differential degrees. Agonist binding to analogous 5-HT and dopamine receptors was not affected by PNU-69176E at 10 M. The drug (Fig. 4) to the human 5-HT 2C receptor in HEK293 cell membranes using a two-site logistic equation
Effects of PNU-69176E at various concentrations on ͓ 3 H͔5-HT (2 nM) binding to the 5-HT 2C receptor were measured in HEK293 cell membranes expressing the receptor using filtration techniques. Their effects on GTP␥ ͓ 35 S͔ binding were measured in the same membrane preparation and as a function of drug concentrations with or without mesulergine in excess (100 M), and they were normalized to the level observed with 5-HT at a saturating concentration (10 M). Mesulergine by itself showed no appreciable effects on GTP␥ ͓ 35 S͔ binding, but it blocked PNU-69176E-induced GTP␥ ͓ 35 S͔ binding. showed no appreciable effect on [ 3 H]5-HT (2 nM) binding to 5-HT 2A , 5-HT 2B , 5-HT 6 , and 5-HT 7A receptors and also no effect on [ 3 H]quinpirole binding to dopamine D2-long and D3 receptors (Fig. 2C) .
Functionally, cloned 5-HT 2C receptors in HEK293 cells couple to both pertussis toxin-insensitive G q/11 (Julius et al., 1988) and pertussis toxin-sensitive G i subtypes of G proteins (Alberts et al., 1999) . GDP/GTP exchange at G␣ subunits is an early step for G protein activation and could be monitored with [
35 S]GTP␥S (a slowly hydrolyzable analog) binding to G␣ i . The exchange at G␣ q/11 is not considerable because of their much slower turnover rates in isolated states (Pang and Sternweis, 1990; Smrcka et al., 1991) . In HEK293-A cells, 5-HT concentration-dependently enhanced mesulergine-sensitive [
35 S]GTP␥S binding, whereas mesulergine by itself showed no appreciable effects on the basal [
35 S]GTP␥S binding (Alberts et al., 1999) . The basal, mesulergine-sensitive [ 35 S]GTP␥S binding, however, increased as a function of PNU-69176E concentrations (Fig. 4) , and its concentrationresponse profile was biphasic and similar to that observed with (Fig. 4) . The stimulatory phase for PNU-69176E displayed an EC 50 value of 7.7 Ϯ 0.6 M and a slope of 2.5 Ϯ 0.3, and its inhibitory phase exhibited an IC 50 value of 49 Ϯ 2 M and a slope of 3.4 Ϯ 0.9 (Table 1) Signaling responses for 5-HT 2C receptors could also be examined with transient IP 3 release in intact cells during a short incubation period (e.g., 1 min) or [ 3 H]IP accumulation during a longer incubation period (e.g., 30 min) in the presence of lithium and pargeline. In this study, 5-HT (10 M) transiently increased IP 3 releases in HEK293 cells, reaching a peak at the incubation time of 45 s. PNU-69176E (10 M) by itself also increased IP 3 releases with the same time course and a peak that reached 71% of the maximal 5-HT (10 M) response (2.4 Ϯ 0.4 pmol/well) ( (Fig. 5) . The drug responses were blocked by mesulergine (10 M), an antagonist to 5-HT 2C . These results are consistent with the view that the drug renders 5-HT 2C receptors constitutively active.
5-HT 2C Positive Allosteric Modulator 81
To investigate potential functional interactions between PNU-690176E and 5-HT, we examined [
35 S]GTP␥S binding as a function of 5-HT concentrations with or without PNU-69176E (10 M) (Fig. 4B) . 5-HT concentration-dependently increased [
35 S]GTP␥S binding with an EC 50 value of 27 Ϯ 4 nM. PNU-69176E at 10 M visibly shifted the 5-HT profile upward. After subtraction of the portion induced by PNU-69176E alone, the 5-HT profile fitted to a single rectangular hyperbola with an EC 50 value of 10 Ϯ 1.2 nM for 5-HT and a maximal level of 120 Ϯ 5%, as normalized to that of 5-HT alone (Fig. 4B) . This indicates that PNU-69176E (10 M) potentiates the 5-HT action by decreasing the EC 50 value from 27 to 10 nM and increasing maximal stimulation by 20%.
We also examined the effect of 5-HT at submaximal (5 nM) and saturating concentrations on IP 3 production with or without PNU-69176E. Peak IP 3 level was measured with a 45-s exposure to 5-HT. At a submaximal concentration of 5 3 H]inositol upon exposure to PNU-69176E at 10 M or 5-HT 10 M for 30 min, following a procedure described elsewhere (Berridge et al., 1982) . The basal level of [ 3 H]IP accumulation was negligible during a 30-min incubation period and was not reduced in the presence of mesulergine (antagonist) at 100 M. The data in A represent the mean Ϯ S.E. from three triplicate concentrationresponse profiles, and those in B represent the mean Ϯ S.E. from two quadruplicate concentration-response profiles. nM, 5-HT induced an IP 3 release of 0.6 Ϯ 0.1 pmol/well, and PNU-69176E (10 M) alone induced an IP 3 release of 1.3 Ϯ 0.2 pmol/well. In combination of the two, the peak IP 3 level reached a nearly maximal level of 1.8 Ϯ 0.2 pmol/well. At a saturating concentration of 200 nM, 5-HT increased IP 3 release by 2.0 Ϯ 0.2 pmol/mg of protein, and its action was not augmented by PNU-69175E at 10 M (2 Ϯ 0.1 pmol/mg of protein). This suggests that PNU-69176E and 5-HT share the same IP 3 signaling pathways, but their functional potentiation was not as evident as with [
35 S]GTP␥S binding, probably because of involvements of downstream amplification and threshold steps for IP 3 release.
In the course of studying the pharmacology of the 5-HT 2C receptor, we obtained several mammalian cell lines, HEK293, SH-EP, and NIH3T3, stably expressing the receptor at various receptor densities, as estimated from maximal binding of [ 3 H]mesulergine (antagonist) ( Table 2 ). The highest receptor density was 45 Ϯ 3 pmol/mg of protein for the HEK293 cell line we studied (HEK293-A), followed by SH-EP-A, NIH3T3, and HEK293-B at receptor densities of 12.4 Ϯ 2, 11.9 Ϯ 0.6, and 6.6 Ϯ 0.1 pmol/mg of protein, respectively. Despite widely variable receptor densities, all of these cell lines showed robust agonist-induced [
35 S]GTP␥S binding, which was blocked by N-ethylmaleimide (100 M), an inhibitor of G i and G o subtypes of G proteins (data not shown). Also, PNU-69176E enhanced the affinity of 5-HT to low-affinity sites and increased the basal, mesulergine-sensitive [
35 S]GTP␥S binding. The K i value for 5-HT low-affinity sites ranged from 159 to 223 nM in these cell lines and decreased in the presence of PNU-69176E (10 M) to10 to 32 nM ( Table 2 ). The drug (10 M) increased mesulergine-sensitive [
35 S]GTP␥S binding by 23 to 50% as normalized to that of 5-HT at 10 M (Table 1) . We conclude that the positive allosteric modulation of 5-HT 2C receptors by PNU-69176E was not dependent on receptor density or on specific cell lines.
Structurally, PNU-69176E consists of two moieties, a long alkyl chain (undecyl) and a polar moiety including the ␣-Dgalactopyranoside (Fig. 1) . Analogs of PHA-69176E with a shorter alkyl chain (methyl to hexyl) showed no effect on [ 3 H]5-HT binding to 5-HT 2C receptors (Table 3) . PNU-68607E (methyl), PNU-65287E (ethyl), PNU-63502E (propyl), PNU-61734E (n-butyl), PNU-62804E (t-butyl), PNU-67220E (pentanoyl), and PNU-62344E (n-hexyl) at 10 M did not stimulate (Table 3) . These results indicate that the undecyl chain and the specific polar group seem to be essential for PNU-68176E to exert positive allosteric modulation on 5-HT 2C receptors.
Discussion
Allosteric modulations have been reported for several types of G protein-coupled receptors. Muscarinic M 1 and M 2 receptors were allosterically modulated by gallamine, pancuronium, and alcuronium, affecting local ligand binding sites (Tuček and Prošta, 1995) . Various biogenic amine receptors interact with Na ϩ and Zn 2ϩ via the aspartate residue at their second transmembrane segment, leading to changes in the binding properties of some ligands (Schetz and Sibley, 2000 (Carriere et al., 2000) , probably indicating complex conformational perturbations via multiple interaction sites. Overall, these earlier studies have indicated the presence of allosteric modulatory sites at G protein-coupled receptors, but modulatory actions through these sites were limited to local impacts on certain ligandbinding sites, species-dependent modulations, or nonspecific functional perturbations. In this study, we discovered a positive allosteric modulator that was highly selective for 5-HT 2C receptors. PNU-69176E profoundly enhanced [ 3 H]5-HT binding to the human 5-HT 2C receptor by selectively increasing the 5-HT affinity to its low-affinity sites (more than 20-fold), with no effect on antagonist binding, and it also rendered the receptor to be constitutively active, as measured with mesulergine-sensitive [
35 S]GTP␥S binding, transient IP 3 release, and [ 3 H]IP accumulation. These actions of PNU-69176E were not dependent on receptor density or specific cell lines, as shown with several mammalian cell lines (HEK293, NIH3T3, and SH-EP) at various receptor densities (6 to 45 pmol/mg of protein).
Interestingly, the modes of action for PNU-69176E are considerably different from those for conventional allosteric modulators of membrane receptors interacting with a single class of high-affinity sites (e.g., benzodiazepines). First, concentration-response profiles for PNU-69176E showed a Hill molpharm.aspetjournals.org coefficient of nearly 3, indicating multiple cooperative binding sites. Second, the drug induced gradual and uniform conformational changes in the receptor population instead of converting a fractional population to high-affinity states, probably reflecting gradual occupancy of its multiple binding sites. Finally, structurally, PNU-69176E resembles amphipathic lipid metabolites with a long alkyl chain and a polar head group, both of which seem to be essential for its modulatory actions on 5-HT 2C . Thus, various amphipathic lipid metabolites could have modulatory action on 5-HT 2C . In this respect, it is noteworthy that cloned 5-HT 2C receptors expressed in mammalian cells, e.g., NIH3T3 cells, reportedly display some constitutive activity, as monitored with clozapine-or mesulergine-sensitive basal inositol accumulation in intact cells (Barker et al., 1994) . However, no constitutive activity of the 5-HT 2C receptor was detected in isolated membranes from NIH3T3 or HEK293 cells, as measured by [ 35 S]GTP␥S binding and [ 3 H]IP accumulation. It is conceivable that such a constitutive activity could be induced by specific lipid metabolites of relatively short half-lives, thus detectable only in intact cells.
Constitutive activation of G protein-coupled receptors has been frequently reported on mutations at various regions of receptors. This study shows another route of constitutive activation of G protein-coupled receptors, namely allosteric modulation by specific amphipathic compounds and perhaps certain lipid metabolites. 
